In this issue:
Treatment outcomes for SCNSL
Efficacy and safety of AN+AD
Pharmacokinetics, efficacy and safety of mosunetuzumab SC
Characteristics, risk factors and incidence of infections while receiving CD20xCD3 BsAbs
Comparing BsAbs-exposed and BsAbs-naïve patients
Impact and possible synergy of ACAs
Intensive chemotherapy with or without dasatinib
Asciminib versus investigator-selected TKIs
Long-term outcomes of a frontline HMA
Post-HSCT outcomes after receiving AZA/VEN
Please login below to download this issue (PDF)